| Treatment and prognostic impact of transient leukemia in neonates with Down syndrome JH Klusmann, U Creutzig, M Zimmermann, M Dworzak, N Jorch, ... Blood, The Journal of the American Society of Hematology 111 (6), 2991-2998, 2008 | 298 | 2008 |
| Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling JP Bourquin, A Subramanian, C Langebrake, D Reinhardt, O Bernard, ... Proceedings of the National Academy of Sciences 103 (9), 3339-3344, 2006 | 219 | 2006 |
| Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group C Langebrake, U Creutzig, M Dworzak, O Hrusak, E Mejstrikova, ... Journal of Clinical Oncology 24 (22), 3686-3692, 2006 | 173 | 2006 |
| Clinical pharmacists’ interventions in a German university hospital C Langebrake, H Hilgarth Pharmacy world & science 32, 194-199, 2010 | 130 | 2010 |
| Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring C Langebrake, I Brinkmann, A Teigler‐Schlegel, U Creutzig, F Griesinger, ... Cytometry Part B: Clinical Cytometry: The Journal of the International …, 2005 | 117 | 2005 |
| Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement S Viehmann, A Teigler-Schlegel, J Bruch, C Langebrake, D Reinhardt, ... Leukemia 17 (6), 1130-1136, 2003 | 117 | 2003 |
| Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or … C Langebrake, U Creutzig, D Reinhardt Klinische Pädiatrie 217 (03), 126-134, 2005 | 105 | 2005 |
| Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells U Puhlmann, C Ziemann, G Ruedell, H Vorwerk, D Schaefer, ... Journal of Pharmacology and Experimental Therapeutics 312 (1), 346-354, 2005 | 76 | 2005 |
| Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection A Oberle, A Brandt, M Alawi, C Langebrake, S Janjetovic, C Wolschke, ... Haematologica 102 (9), e368, 2017 | 65 | 2017 |
| Potentially inappropriate medication use in multimorbid elderly inpatients: differences between the FORTA, PRISCUS and STOPP ratings B Wickop, S Härterich, C Sommer, A Daubmann, M Baehr, C Langebrake Drugs-real world outcomes 3, 317-325, 2016 | 64 | 2016 |
| Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment D Reinhardt, S Diekamp, C Langebrake, J Ritter, J Stary, M Dworzak, ... Leukemia 19 (8), 1495-1496, 2005 | 52 | 2005 |
| Nationwide Evaluation of Day‐to‐Day Clinical Pharmacists’ Interventions in G erman Hospitals C Langebrake, A Ihbe‐Heffinger, K Leichenberg, S Kaden, M Kunkel, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35 (4 …, 2015 | 50 | 2015 |
| Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression S Gattenloehner, S Chuvpilo, C Langebrake, D Reinhardt, ... Blood, The Journal of the American Society of Hematology 110 (6), 2027-2033, 2007 | 49 | 2007 |
| Do centrally pre-prepared solutions achieve more reliable drug concentrations than solutions prepared on the ward? C Dehmel, SA Braune, G Kreymann, M Baehr, C Langebrake, H Hilgarth, ... Intensive care medicine 37, 1311-1316, 2011 | 47 | 2011 |
| Development and psychometric evaluation of the German version of the Medication Regimen Complexity Index (MRCI‐D) D Stange, L Kriston, C Langebrake, LK Cameron, JD Wollacott, M Baehr, ... Journal of evaluation in clinical practice 18 (3), 515-522, 2012 | 46 | 2012 |
| Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study S Braune, C König, JA Roberts, A Nierhaus, O Steinmetz, M Baehr, ... Critical Care 22, 1-10, 2018 | 38 | 2018 |
| Impact of inaccurate documentation of sampling and infusion time in model-informed precision dosing D Alihodzic, A Broeker, M Baehr, S Kluge, C Langebrake, SG Wicha Frontiers in Pharmacology 11, 172, 2020 | 37 | 2020 |
| Comparison of FORTA, PRISCUS and EU (7)-PIM lists on identifying potentially inappropriate medication and its impact on cognitive function in multimorbid elderly German people … C Krüger, I Schäfer, H van den Bussche, H Bickel, T Dreischulte, A Fuchs, ... BMJ open 11 (9), e050344, 2021 | 29 | 2021 |
| Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation C Langebrake, R Admiraal, E van Maarseveen, A Bonnin, T Bauters Bone Marrow Transplantation 55 (1), 62-69, 2020 | 29 | 2020 |
| Clinical pharmacy services in Germany: a national survey C Schulz, A Fischer, W Vogt, K Leichenberg, U Warnke, A Liekweg, ... European Journal of Hospital Pharmacy 28 (6), 301-305, 2021 | 28 | 2021 |
